Overview

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Caspofungin
Echinocandins
Micafungin